COLD AND FLU VIRUSES have been making people sneeze and hack for millennia. Ancient Egyptians described a flu-like illness on ...

Cholesterol restriction-mediated SREBP1 activation induces noncanonical type I IFNs, including IFN-ω and minor IFN-α subsets, ...

It’s not like no one has tried. In the late ‘90s and early aughts, a now-defunct company, ViroPharma, developed an antiviral ...

IC-MPGN market growth driven by rising prevalence, emerging premium-priced therapies, and off-label treatments addressing chronic immune-related kidney damage in adult populations.Dublin, Dec. 12, ...

Aligos Therapeutics focuses on ALG-000184 for CHB and ALG-055009 for MASH, targeting large, underserved markets with growing ...

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin ResistanceReallocates ...

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024.

2024年11月7日，复旦大学公共卫生学院陈仁杰教授，牛越青年研究员与国家呼吸医学中心中日友好医院杨汀教授研究团队联合开展了一项全国性的病例交叉对照研究，评估大气污染短期暴露对慢阻肺病患者症状急性加重的影响。研究结果发表在呼吸医学期刊Chest上。